;
Author Verified
RCT
Published: Mar 2012
ACE Report #4488
Ace Report Cover Tumour

Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10

Contributing Authors: AM Brufsky WG Harker JT Beck L Bosserman C Vogel C Seidler L Jin G Warsi E Argonza-Aviles J Hohneker SG Ericson EA Perez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

OE EXCLUSIVE

Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.